GlassScriptPhysician profile
Trung Tran
NPI 1609211572
$20,674.23
in general payments reported to CMS, 2019-2025
28 companies · $2,485 in 2025
The $2,485 reported for 2025 was more than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,386 · 2022: $1,542 · 2023: $9,712 · 2024: $5,549 · 2025: $2,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,977 · Food and Beverage: $5,261 · Education: $2,500 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,976.98 |
| Food and Beverage | $5,261.15 |
| Education | $2,500.00 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,219.61 | 2022-2024 | Davinci Xi, Da Vinci Surgical System |
| Atricure, INC. | $5,453.08 | 2021-2025 | Epi-Sense Guided Coagulation System With Visitrax, Atricure Cryoice Cryosphere Cryoablation System, Atriclip Laa Exclusion System |
| Medtronic, INC. | $3,660.18 | 2022-2025 | Simulus, Avalus, Corevalve Evolut R |
| Silk Road Medical, INC. | $1,869.89 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Corcym INC | $1,578.56 | 2024-2025 | Perceval, Mi Detach - Aortic Cross Clamp - Delivery System Kit |
| Edwards Lifesciences Corporation | $394.84 | 2021-2024 | Sapien 3 Ultra Resilia, Mitris Resilia Mitral Valve |
| Abiomed | $363.51 | 2023-2025 | Impella |
| Boston Scientific Corporation | $164.44 | 2025 | Ranger |
| Endologix LLC | $134.48 | 2023 | Alto Abdominal Stent Graft System |
| Galvanize Therapeutics, INC | $121.24 | 2025 | Aliya System |
| Baxter Healthcare | $77.33 | 2021-2023 | Coseal |
| Medical Device Business Services, INC. | $72.36 | 2022 | |
| Livanova USA, INC. | $69.96 | 2023 | Lifesparc |
| Lsi Solutions INC | $63.13 | 2022 | |
| Kls-Martin L.P. | $62.22 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspiremd LTD | $50.95 | 2025 | Cguard Prime Carotid Stent System |
| Teleflex LLC | $43.98 | 2024 | Quikclot |
| Chiesi USA, INC. | $36.75 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $36.18 | 2023-2024 | Xarelto |
| Elutia, INC. | $31.01 | 2022 | |
| Haemonetics Corporation | $30.37 | 2024 | Teg6s Hemostasis System |
| Shockwave Medical, INC | $28.27 | 2025 | |
| Innovation Technologies INC | $23.84 | 2024 | Irrisept |
| Esperion Therapeutics, INC. | $20.18 | 2025 | Nexletol |
| Midsouth Orthopedics INC. | $18.52 | 2024 | |
| Zimmer Biomet Holdings, INC. | $16.78 | 2021 | |
| Merck Sharp & Dohme LLC | $16.46 | 2024 | Verquvo |
| Stryker Corporation | $16.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trung Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.